HTB

Review of COVID-19 in people with immune suppression

Simon Collins, HIV i-Base

A recent review in CID looks at the increasing literature on COVID-19 in a range of different health conditions associated with immune suppression.

These populations includes cancer, hematologic malignancy, solid organ transplant, patients taking biologics and targeted disease modifying anti-rheumatic drugs, primary immunodeficiency, and HIV infection.

The review concludes that with malignancy and solid organ transplant recipients, there might  be at increased risk of severe COVID-19 disease and including higher mortality.

Evidence for other types of immunosuppression is less clear however, with further research, ideally prospective studies to determine the attributable risk of immunocompromising conditions and therapies on COVID-19 disease prognosis.

comment

This paper was mainly included to highlight the impact of COVID-19 on related health conditions. The HIV review is useful, but HTB has reported on additional recent HIV coinfection studies. [2, 3]

Reference

  1. Fung M et al. COVID-19 in immunocompromised hosts: what we know so far. Clinical Infectious Diseases, ciaa863. DOI: 10.1093/cid/ciaa863. (27 June 2020).
    https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa863/5864040
  2. Latest studies on HIV/COVID-19 coinfection. HTB 8(5). (26 June 2020).
    https://i-base.info/htb/38257
  3. Collins S. HIV and COVID-19 coinfection: case reports, retrospective cohorts and outcomes. HTB, HIV/COVID-19 supplement (4). (1 June 2020).
    https://i-base.info/htb/38000

Links to other websites are current at date of posting but not maintained.